Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol.

Date publication

mai 2023

Journal

Journal of neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHASTAGNER Pascal , Dr NGUYEN-THI Phi Linh

Tous les auteurs :
Merlin MS, Schmitt E, Mezloy-Destracque M, Dufour C, Riffaud L, Puiseux C, De Carli E, Bodet D, Icher C, Doz F, Faure-Conter C, Pagnier A, Pluchart C, Thouvenin-Doulet S, Lejeune J, Nguyen Thi PL, Chastagner P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37171700

Résumé

The HIT-SKK protocol is used for low/standard-risk medulloblastomas in young children with the aim to eliminate cranial irradiation and its neuropsychological (NP) sequelae. This therapy includes IV and intraventricular (ITV) methotrexate (MTX) potentially responsible for leukoencephalopathy (LE) and neurocognitive disorders. This study describes the risk factors and course of LE, and investigates its correlation with neurocognitive impact.

Mots clés

Leukoencephalopathy, Medulloblastoma, Methotrexate, Neurocognitive disorders, Quality of life

Référence

J Neurooncol. 2023 05 12;: